Skip to main content
. 2021 Dec 14;13(12):2508. doi: 10.3390/v13122508

Figure 6.

Figure 6

6MMPr increases the conversion to the active form of nucleobase T-1105 but not of its nucleoside analog T-1106. Huh7 cells were inoculated with DENV-2 and treated with DMSO, the nucleobase T-1105 (52.5 µM), 6MMPr (0.1 µM), and the T-1105/6MMPr co-treatment. After 12, 24, 36, and 48 hpt, supernatants were analyzed for viral titers (expressed as PFU/mL in (A) and cells were fixed and prepared for LC/MS/MS analysis of T-1105 ribonucleoside-5’-monophosphate (T-1105-RMP in (C)), T-1105 ribonucleoside-5´-diphosphate (T-1105-RDP in (E)), and T-1105 ribonucleoside-5´-triphosphate (T-1105 RTP in (G)). Similar assay was performed for the nucleoside T-1106 (150 µM) and co-treatment with 6MMPr. Graph in (B) indicates the viral titers. (D,F,H) correspond to the T-1106 5´ monophosphate (T-1106-MP), the T-1106 5´ diphosphate (T-1106-DP), and the T-1106 5´ triphosphate (T-1106-TP) forms, respectively. Mono-, di-, and tri-phosphate levels are expressed as the peak area normalized vs. the amount of total protein of each sample (area/µg protein). The plots represent the mean ± SEM of two independent experiments. * p ≤ 0.05; ** p ≤ 0.005. ND, none detected; black dotted line, limit of detection.